1.26  -1.84 (-59.35%)		12-02 16:00
Open: 3.16 High: 3.23 Volume: 10,428,964		Pre. Close: 3.1 Low: 1.26 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.

Tue, 02 Dec 2025
Sonnet BioTherapeutics (NASDAQ: SONN) gets stockholder OK for Hyperliquid Strategies business combination - Stock Titan

Tue, 02 Dec 2025
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination - GlobeNewswire

Tue, 02 Dec 2025
Sonnet BioTherapeutics Stockholders Approve Business Combination with Hyperliquid Strategies Inc and Rorschach I LLC - Quiver Quantitative

Tue, 02 Dec 2025
Hyperliquid Strategies (Nasdaq: PURR) to Begin Trading December 3 After Sonnet Deal - Stock Titan

Tue, 02 Dec 2025
Lowenstein Represents Sonnet BioTherapeutics in Closing of Business Combination with Hyperliquid Strategies - Lowenstein Sandler LLP

Tue, 02 Dec 2025
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date